Ogasawara Sadahisa, Choo Su-Pin, Li Jiang-Tao, Yoo Changhoon, Wang Bruce, Lee Dee, Chow Pierce K H
Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan.
Curie Oncology, 38 Irrawaddy Road #08-21/29, Mount Elizabeth Novena Specialist Centre, Singapore 329563, Singapore.
Cancers (Basel). 2021 May 27;13(11):2626. doi: 10.3390/cancers13112626.
Hepatocellular carcinoma (HCC) is the fourth most common driver of cancer-related death globally, with an estimated 72% of cases in Asia. For more than a decade, first-line systemic treatments for advanced or unresectable HCC were limited to the multi-targeted kinase inhibitors sorafenib and, more recently, lenvatinib. Now, treatment options have expanded to include immunotherapy, as exemplified by the immune checkpoint inhibitor (ICI) atezolizumab combined with the antiangiogenic agent bevacizumab. Additional combinations of ICIs with kinase inhibitors, other ICIs, or antiangiogenic agents are under investigation, further supporting the new era of immunotherapy for first-line treatment of advanced or unresectable HCC. We describe this evolving landscape and provide expert opinion on therapeutic best practices in the Asia-Pacific region, where different costs of, and patient access to, treatment are a challenge. With the combination of atezolizumab plus bevacizumab likely to become the clinical standard of care, optimising treatment sequence and ensuring patient access to newer therapies remain priorities. Cost containment and treatment sequencing may be facilitated by characterisation of predictive positive and negative biomarkers. With these considerations in mind, this review and expert opinion focused on advanced HCC in the Asia-Pacific region offers perspectives of multiple stakeholders, including physicians, payer systems, and patients.
肝细胞癌(HCC)是全球第四大常见的癌症相关死亡原因,估计72%的病例在亚洲。十多年来,晚期或不可切除HCC的一线全身治疗仅限于多靶点激酶抑制剂索拉非尼,以及最近的仑伐替尼。现在,治疗选择已扩大到包括免疫疗法,以免疫检查点抑制剂(ICI)阿替利珠单抗联合抗血管生成药物贝伐单抗为例。ICI与激酶抑制剂、其他ICI或抗血管生成药物的其他联合方案正在研究中,这进一步支持了晚期或不可切除HCC一线治疗免疫疗法的新时代。我们描述了这一不断演变的格局,并就亚太地区的治疗最佳实践提供专家意见,在该地区,治疗成本和患者获得治疗的机会存在挑战。随着阿替利珠单抗加贝伐单抗的联合治疗可能成为临床标准治疗方案,优化治疗顺序并确保患者能够获得更新的治疗方法仍然是优先事项。通过对预测性阳性和阴性生物标志物的特征分析,可能有助于控制成本和确定治疗顺序。考虑到这些因素,本针对亚太地区晚期HCC的综述和专家意见提供了包括医生、支付系统和患者在内的多个利益相关者的观点。